# Open Label Extension Study to Protocol C2/13/DR-6MP-02

> **NCT01433432** · PHASE2 · WITHDRAWN · sponsor: **Teva GTC**

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** 80 mg DR-6MP

## Key facts

- **NCT ID:** NCT01433432
- **Lead sponsor:** Teva GTC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2011-10
- **Primary completion:** 2012-06
- **Final completion:** 2012-08
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor withdrew support for study due to reorganization and project prioritization
- **Last updated:** 2013-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01433432

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01433432, "Open Label Extension Study to Protocol C2/13/DR-6MP-02". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01433432. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*